Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs

作者：Dunne Julia^*; Rodriguez William J; Murphy Dianne; Beasley B Nhi; Burckart Gilbert J; Filie Jane D; Lewis Linda L; Sachs Hari C; Sheridan Philip H; Starke Peter; Yao Lynne P

来源：Pediatrics, 2011, 128(5): E1242-E1249.

DOI：10.1542/peds.2010-3487

• extrapolation
• efficacy
• pediatric drug-development programs

OBJECTIVES: In 1994, the US Food and Drug Administration (FDA) proposed an approach, based on extrapolation of efficacy findings from adults to the pediatric population, to maximize the use of adult data and other data when designing pediatric drug-development programs. We examined the experience of the FDA in using extrapolation to evaluate how and when it was used and any changes in scientific assumptions over time.
METHODS: We reviewed 370 pediatric studies submitted to the FDA between 1998 and 2008 in response to 159 written requests (166 products) issued under the Pediatric Exclusivity Provision. We identified cases in which efficacy was extrapolated from adult data or other data, we categorized the type of pediatric data required to support extrapolation, and we determined whether the data resulted in new pediatric labeling.
RESULTS: Extrapolation of efficacy from adult data occurred for 82.5% of the drug products (137 of 166). Extrapolation was defined as complete for 14.5% of the products (24 of 166) and partial for 68% of them (113 of 166). Approaches to extrapolation changed over time for 19% of the therapeutic indications studied (13 of 67). When extrapolation was used, 61% of the drug products (84 of 137) obtained a new pediatric indication or extension into a new age group; this number decreased to 34% (10 of 29) when there was no extrapolation.
CONCLUSIONS: Extrapolating efficacy from adult data or other data to the pediatric population can streamline pediatric drug development and help to increase the number of approvals for pediatric use. Pediatrics 2011; 128: e1242-e1249

• 出版日期2011-11